Accueil > Actualité
Actualite financiere : Actualite bourse

GSK: EU approval for HIV prevention

(CercleFinance.com) - GSK, through ViiV Healthcare, has announced that the European Commission has authorised Apretude (long-acting (LA) cabotegravir injection and tablets) for HIV prevention.


ViiV Healthcare is a global HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders,

Cabotegravir is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in high-risk adults and adolescents (aged at least 12 years) weighing at least 35 kg.


Copyright (c) 2023 CercleFinance.com. All rights reserved.
 

societes

marches

tendances

 
Qui sommes-nous ? | Nous contacter | FAQ | Mentions légales | RSS | © Copyright 2007 Cercle Finance. Tous droits réservés.